CONSENSUS STATEMENT ON THE USE OF GnRH ANALOGS IN CHILDREN
Key words: Precocious puberty, GnRH analogs, Development
The development of Gonadotropin Releasing Hormone analogs (GnRHa) revolutionized the
treatment of central precocious puberty (CPP). However, questions remain regarding their
optimal use in CPP and other conditions in children. The European Society for Paediatric
Endocrinology and the Lawson Wilkins Pediatric Endocrine Society convened a Consensus
conference to review the clinical use of GnRHa in children and adolescents. To optimize
the generalizability of the statement, consideration was given to the representations from
North America (United States and Canada) and Europe, an equal male/female ratio,
and a balanced spectrum of professional seniority and expertise when selecting the 30 participants.
The group came to the following unanimous conclusions: the efficacy of GnRHa
to increase adult height is undisputed only in early onset CPP. Other key areas, such as the
psychosocial effects of CPP and their modulation by GnRHa, need further study. Literature
review and consensus process did not provide support for commonly voiced concerns
regarding the use of GnRHa, such as promotion of weight gain or long-term diminution of
bone mineral density. Use of GnRHa in conditions other than CPP requires further investigation
and cannot be routinely suggested.
Vuoi citare questo contributo?
L'accesso è riservato agli abbonati
alla rivista che si siano registrati.
Per accedere all'articolo in formato full text è necessario inserire username e password.
L'immissione di nuovi contenuti è riservata ai soli utenti registrati